Ageless Future Add us as a preferred source on Google

Regan Archibald, LAc, FMP, is the Co-Founder and CEO of Ageless Future, a precision longevity medicine company that designs personalized biological operating systems for high-performing individuals.He is also Co-Founder and CEO of Ageless Pharma RX, a concierge 503A compounding pharmacy delivering advanced peptide, hormone, and regenerative protocols with clinical oversight.Regan is the author of The Peptide Blueprint and the inventor of the Peptide Pathway Bypass™, a patented signal-mapping system that aligns blood chemistry with targeted peptide protocols to restore disrupted cellular communication.For more than two decades, he has worked at the intersection of functional medicine, regenerative therapies, and performance optimization. His work focuses on building structured, repeatable longevity systems centered on four pillars: muscle integrity, cardiovascular durability, cognitive performance, and cellular resilience.Regan serves as Medical Advisor to the Davinci 50 Age Reversal Mastermind and has delivered over 100 private longevity summits worldwide — including executive retreats with YPO, Genius Network, and other high-level entrepreneurial communities.He is known for translating complex longevity science into structured execution plans that reduce biological age and extend performance span — without guesswork.His mission is simple: standardize personalized longevity systems as the future of healthcare.**Any video on this channel is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Some molecules discussed are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use. They are mentioned only in the context of scientific literature and are not being recommended, prescribed, or sold through this content. Do not start, stop, or change any medication, peptide, or supplement based on these videos. All medical decisions must be made with a licensed clinician after pr